Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.49 |
| ▸ | RARB | P10826 | 5/20 | 0.43 |
| ▸ | RARG | P13631 | 5/20 | 0.43 |
| ▸ | RARA | P10276 | 4/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 2/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL720137 | 0.78 | NOTUM (0.50) | NOTUMRARBRARGRARAPTGS1 | |
| SCHEMBL2434643 | 0.78 | NOTUM (0.50) | NOTUMRARBRARGRARAPTGS1 | |
| SCHEMBL2631356 | 0.77 | NOTUM (0.49) | NOTUMRARBRARGRARAPTGS1 | |
| SCHEMBL16178963 | 0.77 | NOTUM (0.49) | NOTUMRARBRARGRARAPTGS1 | |
| SCHEMBL8982307 | 0.77 | NOTUM (0.49) | NOTUMRARBRARGRARAPTGS1 | |
| SCHEMBL2618847 | 0.77 | BACE1 (0.50) | NOTUMRARBRARGRARAPTGS1 | |
| SCHEMBL3797296 | 0.74 | ACACB (0.36) | NOTUMACACB | |
| SCHEMBL10158656 | 0.74 | NOTUM (0.47) | NOTUMRARBRARGRARAPTGS1 | |
| SCHEMBL12604316 | 0.74 | NOTUM (0.47) | NOTUMRARBRARGRARAPTGS1 | |
| SCHEMBL12169410 | 0.74 | NOTUM (0.47) | NOTUMRARBRARGRARAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178547-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178547-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-05-15 | — | — | US | disclosed |
| US-8158803-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158803-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-04-17 | — | — | US | disclosed |
| US-20100272677-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | LEE EUN KYUNG | 2010-10-28 | — | — | US | disclosed |
| US-20100272677-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | LEE EUN KYUNG | 2010-10-28 | — | — | US | disclosed |
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | STEINER SANDRA | 2010-06-24 | — | — | US | disclosed |
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | STEINER SANDRA | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100272677-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | POLR2A, EIF2AK2, RRM2B | NOTUM 3446/4885RARB 742/4885RARG 1316/4885 |
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | RFC1, RRP1B, RRBP1 | NOTUM 4191/4885RARB 584/4885RARG 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.